Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510184 · ClinicalTrials.gov registry record · Phase 3
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
NCT01510184 is a Phase 3 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT01510184, a Phase 3 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.
Interventions
- DRUG Rituximab
- DRUG Zevalin
- DRUG Y-90-Zevalin
- DRUG In-111 Zevalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2012-04-19 |
| Est. Completion | 2014-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01510184
The ClinicalTrials.gov registry entry for NCT01510184 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT01510184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01510184 about?
NCT01510184 is a clinical study titled "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy". The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.
What is the current status of trial NCT01510184?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2012-04-19. Estimated completion is 2014-10-23.
What interventions are being tested in trial NCT01510184?
The interventions under investigation include: Rituximab (DRUG), Zevalin (DRUG), Y-90-Zevalin (DRUG), In-111 Zevalin (DRUG).
Who is sponsoring clinical trial NCT01510184?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.